(FILE 'REGISTRY' ENTERED AT 12:53:17 ON 22 NOV 2004)
L13 STR

Str.



REP G1=(3-3) CH2
NODE ATTRIBUTES:
CONNECT IS X2 RC AT 4
CONNECT IS X2 RC AT 5
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L15 2838 SEA FILE=REGISTRY SSS FUL L13
L26 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS PCY AT 16
GGCAT IS MCY UNS AT 29
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

Searcher : Shears 571-272-2528

STEREO ATTRIBUTES: NONE
L27 3 SEA FILE=REGISTRY SUB=L15 SSS FUL L26

100.0% PROCESSED 74 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 12:57:42 ON 22 NOV 2004
L28 3 S L27

L28 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:112150 CAPLUS
DOCUMENT NUMBER: 110:112150
TITLE: Luliberin peptide analog for stimulation of production of roe during artificial milting of common tench (Tinca tinca), trout (Micropterus samonides) and sheatfish (Silurus glanis)
INVENTOR(S): Kouril, Jan; Hamackova, Jitka; Machacek, Jiri; Barth, Tomislav; Flegel, Martin
PATENT ASSIGNEE(S): Czech.
SOURCE: Czech., 8 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Czech
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 244397	B1	19860717	CS 1984-8441	19841006
PRIORITY APPLN. INFO.:			CS 1984-8441	19841006

AB A method of obtaining roe during artificial milting of T. tinca, M. samonides, and S. glanis is characterized by injecting female egg-carrying fish, during premilting maturity, i.m. with Glu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-NHEt (I), an analog of luliberin, at 5-20 μg/kg. Female egg-carrying tench (500-1000 g, 4-5 yr) at 20-22° were injected i.m. with I (5-80 μg/kg). Within 15 h, the roe were ready for milting. A dosage of 20 μg/kg resulted in ovulation by 62.5% of the fish. The most effective dosage range was 5-20 μg/kg.

IT **119261-01-7**
RL: BIOL (Biological study)
(ovulation stimulation by, in fish)

RN 119261-01-7 CAPLUS
CN Luteinizing hormone-releasing factor (swine), 1-L-glutamic acid-6-D-alanine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L28 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:556330 CAPLUS
DOCUMENT NUMBER: 109:156330
TITLE: Reversed-phase high-performance liquid chromatography of fertirelin acetate and related compounds
AUTHOR(S): Hartman, Patrick A.; Stodola, John D.
CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: Journal of Chromatography (1988), 444, 177-82
CODEN: JOCRAM; ISSN: 0021-9673

Searcher : Shears 571-272-2528

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Separation of fertirelin acetate (FA) from process impurities, potential degradation products and related peptides including LH releasing hormone was achieved by reversed-phase HPLC. A number of chromatog. conditions (column type mobile phase composition, isocratic/gradient elution) and detection systems were utilized to examine the bulk drug and formulation of FA. Examples of sepns. designed for potency and impurity detns. are described. Complete recovery of FA is obtained with an isocratic HPLC system. An external standard method is used to determine potency with a precision of <1%
R.S.D. A gradient HPLC system is used to determine impurities with a precision
of 5-10% R.S.D. at the 1-2% impurity level. As little as .apprx.0.1% (area %) of related peptides are detected at 214 mn.

IT **116921-32-5**
RL: ANT (Analyte); ANST (Analytical study)
(HPLC of, as fertirelin acetate impurity)

RN 116921-32-5 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 1-L-glutamic acid-9-(N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L28 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:82207 CAPLUS
DOCUMENT NUMBER: 108:82207
TITLE: HPLC of leuprolide acetate in injectable solutions
AUTHOR(S): Sutherland, J. W.; Menon, G. N.
CORPORATE SOURCE: Pharm. Prod. Div., Abbott Lab., North Chicago, IL, 60064, USA
SOURCE: Journal of Liquid Chromatography (1987), 10(10), 2281-9
CODEN: JLCHD8; ISSN: 0148-3919
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A stability-indicating HPLC method based on a 5-μ octadecylsilane column and pH 6.5 0.057M aqueous monobasic ammonium phosphate solution-MeCN (77:23 by volume) mobile phase, and UV detection at 220 nm was used for the determination of leuprolide acetate in injections. Et p-hydroxybenzoate was the internal standard The relative standard deviation was 1.8% and the method was also successfully used for the determination of impurities/precursors occurring during the drug manufacture The drug was more stable at pH 3.3 than at pH 10.3 when heated at 100° for 16 h. Glu1-leuprolide was the major degradation product when the drug was treated with 0.1N HCl at 40° for 48 h.

IT **112642-13-4**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, as leuprolide impurity by HPLc)

RN 112642-13-4 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 1-L-glutamic acid-6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



FILE 'CAOLD' ENTERED AT 12:58:05 ON 22 NOV 2004
L29 0 S L27

FILE 'USPATFULL' ENTERED AT 12:58:10 ON 22 NOV 2004
L30 0 S L27

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 12:58:19 ON 22 NOV 2004
L31 0 S L27

Searcher : Shears 571-272-2528

(FILE 'MARPAT' ENTERED AT 12:58:35 ON 22 NOV 2004)

L32 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 16 29
GGCAT IS PCY AT 16
GGCAT IS MCY UNS AT 29
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L34 92 SEA FILE=MARPAT SSS FUL L32 (MODIFIED ATTRIBUTES)
L35 STR



REP G1=(3-3) CH2
NODE ATTRIBUTES:
CONNECT IS X2 RC AT 4
CONNECT IS X2 RC AT 5

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L36 6 SEA FILE=MARPAT SUB=L34 SSS FUL L35 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 82 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L36 ANSWER 1 OF 6 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 141:162339 MARPAT
TITLE: Improved linkers for pharmaceutical compounds
INVENTOR(S): De Haeen, Christoph; Nunn, Adrian; Swenson, Rolf E.
PATENT ASSIGNEE(S): Bracco Imaging S.P.A., Italy
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062574	A2	20040729	WO 2003-US41656	20031224

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-439722P 20030113

AB A new and improved method for extending the half life of pharmaceutical compds. for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N-O-P-Q, wherein M is the diagnostic or therapeutic moiety, N-O-P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compds. may have the formula M-N-O-P-M, wherein M is independently a diagnostic or therapeutic moiety and N-O-P is the linker of the invention. Methods for imaging or treating a patient using the compds. of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compds. are

further provided, as are methods for preparing a radiotherapeutic agent from the compds.

IC ICM A61K

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 8, 26, 34

ST imaging agent targeted conjugate prepn bile acid; radiotherapeutic targeted conjugate prepn

IT Imaging agents
(NMR contrast; targeted diagnostic and therapeutic agents with improved half life)

IT Imaging agents
(acoustic; targeted diagnostic and therapeutic agents with improved half life)

IT Antibiotics
(conjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Antibodies and Immunoglobulins
Interleukin 1
Neurokinins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Enzymes, biological studies
Growth factors, animal
Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Drug delivery systems
(immunoconjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Drug delivery systems
(injections; targeted diagnostic and therapeutic agents with improved half life)

IT Human
Imaging agents
Photodynamic therapy
Phototherapy
Radiopharmaceuticals
Radiotherapy
Test kits
(targeted diagnostic and therapeutic agents with improved half life)

IT Amino acids, biological studies
Bile acids
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeted diagnostic and therapeutic agents with improved half life)

IT 7440-54-2D, Gadolinium, cholic acid and peptide-conjugated complexes
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(targeted diagnostic and therapeutic agents with improved half life)

IT 721937-44-6DP, Lutetium 177 complexes 721937-46-8DP, Lutetium 177/Indium 111/Gadolinium complexes
RL: DGN (Diagnostic use); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(targeted diagnostic and therapeutic agents with improved half life)

IT 14265-75-9DP, 177Lu, cholic acid and peptide-conjugated complexes, biological studies
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(targeted diagnostic and therapeutic agents with improved half life)

IT 83-44-3DP, Deoxycholic acid, conjugates 14158-31-7DP, Iodine 125, insulin derivs. labeled with, biological studies 721937-42-4DP, complexes 721937-44-6DP, complexes 721937-46-8DP, complexes 721937-48-0DP, complexes 721937-50-4DP, complexes 721937-52-6DP, complexes 721937-54-8DP, complexes 728038-66-2DP, complexes 728919-39-9DP, Indium 111 complexes
RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(targeted diagnostic and therapeutic agents with improved half life)

IT 50-56-6D, Oxytocin, conjugates 58-82-2D, Bradykinin, conjugates 69-79-4D, Maltose, conjugates 113-79-1D, Arginine vasopressin, conjugates 9002-79-3D, MSH, conjugates 9011-97-6D, CCK, conjugates 9034-40-6D, LH-RH, conjugates 15750-15-9D, Indium 111, conjugated complexes, biological studies 33507-63-0D, Substance P, conjugates 37221-79-7D, VIP, conjugates 51110-01-1D, Somatostatin, conjugates 62229-50-9D, EGF, conjugates 82785-45-3D, Neuropeptide Y, conjugates 83150-76-9D, Octreotide, conjugates 106526-69-6D, conjugates 108736-35-2D, Lanreotide, conjugates 116243-73-3D, Endothelin, conjugates 153582-79-7D, conjugates 208253-06-9D, conjugated complexes 455892-74-7D, conjugates 728038-56-0D, conjugates 728038-57-1D, conjugates 728038-58-2D, conjugates 728038-59-3 728912-33-2D, Galanan, conjugates 728919-36-6 728919-37-7 728919-39-9
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeted diagnostic and therapeutic agents with improved half life)

IT 99-33-2 108-30-5, reactions 29022-11-5 38359-38-5 106697-50-1 135053-62-2 157692-53-0 721939-41-9D, resin-bound 721939-45-3 728038-68-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(targeted diagnostic and therapeutic agents with improved half life)

IT 106526-69-6P 153582-79-7P 455892-74-7P 721939-40-8P 721939-49-7P 721939-52-2P 728038-60-6P 728038-61-7P 728038-63-9P 728038-64-0P 728038-67-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(targeted diagnostic and therapeutic agents with improved half life)

IT 728038-62-8P 728038-65-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(targeted diagnostic and therapeutic agents with improved half life)

IT 9004-10-8D, Insulin, conjugates
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeted diagnostic and therapeutic agents with improved half life)

L36 ANSWER 2 OF 6 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 141:47383 MARPAT
TITLE: Peptides having antiangiogenic activity
INVENTOR(S): Haviv, Fortuna; Henkin, Jack; Bradley, Michael F.; Kalvin, Douglas M.; Schneider, Andrew J.
PATENT ASSIGNEE(S): USA

SOURCE: U.S., 27 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6753408	B1	20040622	US 2000-718591	20001122
PRIORITY APPLN. INFO.:			US 1999-166791P	19991122

AB Peptides Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compns. and methods of inhibiting angiogenesis in a mammal. Compds. such as N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-ProNH-Et were prepared The compds. inhibited human endothelial cell migration by at least 50 % inhibition when tested at concns. of 1 nM.

IC ICM C07K007-00
NCL 530328000
CC 1-12 (Pharmacology)
Section cross-reference(s): 34
ST antiangiogenic peptide; endothelial cell migration inhibition peptide
IT Blood vessel
(microvessel, endothelium, inhibition of migration of cells of, of human; peptides having antiangiogenic activity)
IT Cell migration
(of human microvascular endothelial cells, inhibition of; peptides having antiangiogenic activity)
IT Angiogenesis inhibitors
Antitumor agents
Drug delivery systems
Human
Mammalia
(peptides having antiangiogenic activity)
IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides having antiangiogenic activity)
IT 341522-16-5P 341522-18-7P 341522-20-1P 341522-22-3P 341522-24-5P
341522-29-0P 341522-35-8P 341522-37-0P 341522-39-2P 341522-41-6P
341522-43-8P 341522-45-0P 341522-47-2P 341522-49-4P 341522-51-8P
341522-53-0P 341522-55-2P 341522-57-4P 341522-59-6P 341522-61-0P
341522-63-2P 341522-65-4P 341522-67-6P 341522-69-8P 341522-72-3P
341522-74-5P 341522-96-1P 341523-09-9P 341523-13-5P 341523-15-7P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having antiangiogenic activity)
IT 341522-27-8 341522-31-4 341522-33-6 341522-94-9 341522-98-3
341523-03-3 341523-07-7 708208-86-0 708208-87-1 708208-88-2
708208-89-3
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides having antiangiogenic activity)
IT 341522-17-6P 341522-19-8P 341522-21-2P 341522-23-4P 341522-25-6P

341522-30-3P 341522-32-5P 341522-34-7P 341522-36-9P 341522-38-1P
341522-40-5P 341522-42-7P 341522-44-9P 341522-46-1P 341522-48-3P
341522-50-7P 341522-52-9P 341522-54-1P 341522-56-3P 341522-58-5P
341522-60-9P 341522-62-1P 341522-64-3P 341522-66-5P 341522-68-7P
341522-70-1P 341522-73-4P 341522-75-6P 341522-77-8P 341522-79-0P
341522-81-4P 341522-83-6P 341522-85-8P 341522-87-0P 341522-89-2P
341522-91-6P 341522-93-8P 341522-95-0P 341522-97-2P 341522-99-4P
341523-04-4P 341523-08-8P 341523-10-2P 341523-14-6P 341523-16-8P
708208-90-6P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having antiangiogenic activity)
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 3 OF 6 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 140:321722 MARPAT
TITLE: Preparation of peptide antiangiogenic drugs
INVENTOR(S): Henkin, Jack; Haviv, Fortuna; Bradley, Michael F.; Kalvin, Douglas M.; Schneider, Andrew J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 84 pp., Cont.-in-part of U.S. Ser. No. 316,888.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6716963	B1	20040406	US 1999-447226	19991122
US 6774211	B1	20040810	US 2001-833196	20010411
PRIORITY APPLN. INFO.:			US 1998-86536P	19980522
			US 1999-126546P	19990326
			US 1999-316888	19990521
			US 1999-447226	19991122

AB Peptides A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 (A0 is an acyl group; A10 is OH, an amino group, or an amino acid amide; A1-9 are amino acyl residues) or their pharmaceutically acceptable salts, esters, solvates, or prodrugs were prepared for the treatment of angiogenesis. Thus, N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-NHEt was prepared by the solid-phase method and assayed for in vitro angiogenic activity (87.3 and 76.9% inhibition at 20 nM and 10 nM. resp.).
IC ICM C07K007-00
NCL 530328000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
ST peptide prepn antiangiogenic activity
IT Solid phase synthesis
(peptide; preparation of peptide antiangiogenic drugs)
IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of peptide antiangiogenic drugs)

IT Peptides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 251579-31-4P 251579-32-5P 251579-33-6P 251579-34-7P 251579-35-8P
251579-36-9P 251579-37-0P 251579-38-1P 251579-39-2P 251579-40-5P
251579-41-6P 251579-42-7P 251579-43-8P 251579-44-9P 251579-45-0P
251579-46-1P 251579-47-2P 251579-48-3P 251579-49-4P 251579-50-7P
251579-51-8P 251579-52-9P 251579-53-0P 251579-54-1P 251579-55-2P
251579-56-3P 251579-57-4P 251579-58-5P 251579-59-6P 251579-60-9P
251579-61-0P 251579-62-1P 251579-63-2P 251579-64-3P 251579-65-4P
251579-66-5P 251579-67-6P 251579-68-7P 251579-69-8P 251579-70-1P
251579-71-2P 251579-72-3P 251579-73-4P 251579-74-5P 251579-75-6P
251579-76-7P 251579-77-8P 251579-78-9P 251579-79-0P 251579-80-3P
251579-81-4P 251579-82-5P 251579-83-6P 251579-84-7P 251579-85-8P
251579-86-9P 251579-87-0P 251579-88-1P 251579-89-2P 251579-90-5P
251579-91-6P 251579-92-7P 251579-93-8P 251579-94-9P 251579-95-0P
251579-96-1P 251579-97-2P 251579-98-3P 251579-99-4P 251580-00-4P
251580-01-5P 251580-02-6P 251580-03-7P 251580-04-8P 251580-05-9P
251580-06-0P 251580-07-1P 251580-08-2P 251580-09-3P 251580-10-6P
251580-11-7P 251580-12-8P 251580-13-9P 251580-14-0P 251580-15-1P
251580-16-2P 251580-17-3P 251580-18-4P 251580-19-5P 251580-20-8P
251580-21-9P 251580-22-0P 251580-23-1P 251580-24-2P 251580-25-3P
251580-26-4P 251580-27-5P 251580-28-6P 251580-29-7P 251580-30-0P
251580-31-1P 251580-32-2P 251580-33-3P 251580-34-4P 251580-35-5P
251580-36-6P 251580-37-7P 251580-38-8P 251580-39-9P 251580-40-2P
251580-41-3P 251580-42-4P 251580-43-5P 251580-44-6P 251580-45-7P
251580-46-8P 251580-47-9P 251580-48-0P 251580-49-1P 251580-50-4P
251580-51-5P 251580-52-6P 251580-54-8P 251580-55-9P 251580-57-1P
251580-58-2P 251580-60-6P 251580-61-7P 251580-63-9P 251580-64-0P
251580-66-2P 251580-67-3P 251580-69-5P 251580-70-8P 251580-72-0P
251580-73-1P 251580-75-3P 251580-76-4P 251580-78-6P 251580-79-7P
251580-81-1P 251580-82-2P 251580-84-4P 251580-85-5P 251580-87-7P
251580-88-8P 251580-90-2P 251580-91-3P 251580-93-5P 251580-94-6P
251580-96-8P 251580-97-9P 251580-99-1P 251581-00-7P 251581-02-9P
251581-03-0P 251581-05-2P 251581-07-4P 251581-08-5P 251581-10-9P
251581-11-0P 251581-13-2P 251581-14-3P 251581-15-4P 251581-16-5P
251581-17-6P 251581-18-7P 251581-19-8P 251581-20-1P 251581-21-2P
251581-22-3P 251581-23-4P 251581-24-5P 251581-25-6P 251581-26-7P
251581-27-8P 251581-28-9P 251581-29-0P 251581-30-3P 251581-31-4P
251581-32-5P 251581-33-6P 251581-34-7P 251581-35-8P 251581-36-9P
251581-37-0P 251581-38-1P 251581-39-2P 251581-40-5P 251581-41-6P
251581-42-7P 251581-43-8P 251581-44-9P 251581-45-0P 251581-46-1P
251581-47-2P 251581-48-3P 251581-49-4P 251581-50-7P 251581-51-8P
251581-52-9P 251581-53-0P 251581-54-1P 251581-55-2P 251581-56-3P
251581-57-4P 251581-58-5P 251581-59-6P 251581-60-9P 251581-61-0P
251581-62-1P 251581-63-2P 251581-64-3P 251581-65-4P 251581-66-5P
251581-67-6P 251581-68-7P 251581-69-8P 251581-70-1P 251581-71-2P
251581-72-3P 251581-73-4P 251581-74-5P 251581-75-6P 251581-76-7P
251581-77-8P 251581-78-9P 251581-79-0P 251581-80-3P 251581-81-4P
251581-82-5P 251581-83-6P 251581-84-7P 251581-85-8P 251581-86-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

Searcher : Shears 571-272-2528

IT 251581-87-0P 251581-88-1P 251581-89-2P 251581-90-5P 251581-91-6P
251581-92-7P 251581-93-8P 251581-94-9P 251581-95-0P 251581-96-1P
251581-97-2P 251581-98-3P 251581-99-4P 251582-00-0P 251582-01-1P
251582-02-2P 251582-03-3P 251582-04-4P 251582-05-5P 251582-06-6P
251582-07-7P 251582-08-8P 251582-09-9P 251582-10-2P 251582-11-3P
251582-12-4P 251582-13-5P 251582-14-6P 251582-15-7P 251582-16-8P
251582-17-9P 251582-18-0P 251582-19-1P 251582-20-4P 251582-21-5P
251582-22-6P 251582-23-7P 251582-24-8P 251582-25-9P 251582-26-0P
251582-27-1P 251582-28-2P 251582-29-3P 251582-30-6P 251582-31-7P
251582-32-8P 251582-33-9P 251582-34-0P 251582-35-1P 251582-36-2P
251582-37-3P 251582-38-4P 251582-39-5P 251582-40-8P 251582-41-9P
251582-42-0P 251582-43-1P 251582-44-2P 251582-45-3P 251582-46-4P
251582-47-5P 251582-48-6P 251582-49-7P 251582-50-0P 251582-51-1P
251582-52-2P 251582-53-3P 251582-54-4P 251582-55-5P 251582-56-6P
251582-57-7P 251582-58-8P 251582-59-9P 251582-60-2P 251582-61-3P
251582-62-4P 251582-63-5P 251582-64-6P 251582-65-7P 251582-66-8P
251582-67-9P 251582-68-0P 251582-69-1P 251582-70-4P 251582-71-5P
251582-72-6P 251582-73-7P 251582-74-8P 251582-75-9P 251582-76-0P
251582-77-1P 251582-78-2P 251582-79-3P 251582-80-6P 251582-81-7P
251582-82-8P 251582-83-9P 251582-84-0P 251582-85-1P 251582-86-2P
251582-87-3P 251582-88-4P 251582-89-5P 251582-90-8P 251582-91-9P
251582-92-0P 251582-93-1P 251582-94-2P 251582-95-3P 251582-96-4P
251582-97-5P 251582-98-6P 251582-99-7P 251583-00-3P 251583-01-4P
251583-02-5P 251583-03-6P 251583-04-7P 251583-05-8P 251583-06-9P
251583-07-0P 251583-08-1P 251583-09-2P 251583-10-5P 251583-11-6P
251583-12-7P 251583-13-8P 251583-14-9P 251583-15-0P 251583-16-1P
251583-17-2P 251583-18-3P 251583-19-4P 251583-20-7P 251583-21-8P
251583-22-9P 251583-23-0P 251583-24-1P 251583-25-2P 251583-26-3P
251583-27-4P 251583-28-5P 251583-29-6P 251583-30-9P 251583-31-0P
251583-32-1P 251583-33-2P 251583-34-3P 251583-35-4P 251583-36-5P
251583-37-6P 251583-38-7P 251583-39-8P 251583-40-1P 251583-41-2P
251583-42-3P 251583-43-4P 251583-44-5P 251583-45-6P 251583-46-7P
251583-47-8P 251583-48-9P 251583-49-0P 251583-50-3P 251583-51-4P
251583-52-5P 251583-53-6P 251583-54-7P 251583-55-8P 251583-56-9P
251583-57-0P 251583-58-1P 251583-59-2P 251583-60-5P 251583-61-6P
251583-62-7P 251583-63-8P 251583-64-9P 251583-65-0P 251583-66-1P
251583-67-2P 251583-68-3P 251583-69-4P 251583-70-7P 251583-71-8P
251583-72-9P 251583-73-0P 251583-74-1P 251583-75-2P 251583-76-3P
251583-77-4P 251583-78-5P 251583-79-6P 251583-80-9P 251583-81-0P
251583-82-1P 251583-83-2P 251583-84-3P 251583-85-4P 251583-86-5P
251583-87-6P 251583-88-7P 251583-89-8P 251583-90-1P 251583-91-2P
251583-92-3P 251583-93-4P 251583-96-7P 251583-97-8P 251583-98-9P
251583-99-0P 251584-00-6P 251584-01-7P 251584-02-8P 251584-03-9P
251584-04-0P 251584-05-1P 251584-06-2P 251584-07-3P 251584-08-4P
251584-09-5P 251584-10-8P 251584-11-9P 251584-12-0P 251584-13-1P
251584-14-2P 251584-15-3P 251584-16-4P 251584-17-5P 251584-18-6P
251584-19-7P 251584-20-0P 251584-21-1P 251584-22-2P 251584-23-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 251584-24-4P 251584-25-5P 251584-26-6P 251584-27-7P 251584-28-8P
251584-29-9P 251584-30-2P 251584-31-3P 251584-32-4P 251584-33-5P
251584-34-6P 251584-35-7P 251584-36-8P 251584-37-9P 251584-38-0P
251584-39-1P 251584-40-4P 251584-41-5P 251584-42-6P 251584-43-7P
251584-44-8P 251584-45-9P 251584-46-0P 251584-47-1P 251584-48-2P

Searcher : Shears 571-272-2528

251584-49-3P 251584-50-6P 251584-51-7P 251584-52-8P 251584-53-9P
251584-54-0P 251584-55-1P 251584-56-2P 251584-57-3P 251584-58-4P
251584-59-5P 251584-60-8P 251584-61-9P 251584-62-0P 251584-63-1P
251584-64-2P 251584-65-3P 251584-66-4P 251584-67-5P 251584-68-6P
251584-69-7P 251584-70-0P 251584-71-1P 251584-72-2P 251584-73-3P
251584-74-4P 251584-75-5P 251584-76-6P 251584-77-7P 251584-78-8P
251584-79-9P 251584-80-2P 251584-81-3P 251584-82-4P 251584-83-5P
251584-84-6P 251584-85-7P 251584-86-8P 251584-87-9P 251584-88-0P
251584-89-1P 251584-90-4P 251584-91-5P 251584-92-6P 251584-93-7P
251584-94-8P 251584-95-9P 251584-96-0P 251584-97-1P 251584-98-2P
251584-99-3P 251585-00-9P 251585-01-0P 251585-02-1P 251585-03-2P
251585-04-3P 251585-05-4P 251585-06-5P 251585-07-6P 251585-08-7P
251585-09-8P 251585-10-1P 251585-11-2P 251585-12-3P 251585-13-4P
251585-14-5P 251585-15-6P 251585-16-7P 251585-17-8P 251585-18-9P
251585-19-0P 251585-20-3P 251585-21-4P 251585-22-5P 251585-23-6P
251585-24-7P 251585-25-8P 251585-26-9P 251585-27-0P 251585-28-1P
251585-29-2P 251585-30-5P 251585-31-6P 251585-32-7P 251585-33-8P
251585-34-9P 251585-35-0P 251585-36-1P 251585-37-2P 251585-38-3P
251585-39-4P 251585-40-7P 251585-41-8P 251585-42-9P 251585-43-0P
251585-44-1P 251585-45-2P 251585-46-3P 251585-47-4P 251585-48-5P
251585-49-6P 251585-50-9P 251585-51-0P 251585-52-1P 251585-53-2P
251585-54-3P 251585-55-4P 251585-56-5P 251585-57-6P 251585-58-7P
251585-59-8P 251585-60-1P 251585-61-2P 251585-62-3P 251585-63-4P
251585-64-5P 251585-65-6P 251585-66-7P 251585-67-8P 251585-68-9P
251585-69-0P 251585-70-3P 251585-71-4P 251585-72-5P 251585-73-6P
251585-74-7P 251585-75-8P 251585-76-9P 251585-77-0P 251585-78-1P
251585-79-2P 251585-80-5P 251585-81-6P 251585-82-7P 251585-83-8P
251585-84-9P 251585-85-0P 251585-86-1P 251585-87-2P 251585-88-3P
251585-89-4P 251585-90-7P 251585-91-8P 251585-92-9P 251585-93-0P
251585-94-1P 251585-95-2P 251585-96-3P 251585-97-4P 251585-98-5P
251585-99-6P 251586-00-2P 251586-01-3P 251586-03-5P 251586-04-6P
251586-05-7P 251586-06-8P 251586-07-9P 251586-08-0P 251586-09-1P
251586-10-4P 251586-11-5P 251586-12-6P 251586-13-7P 251586-15-9P
251586-16-0P 251586-17-1P 251586-18-2P 251586-19-3P 251586-20-6P
251586-21-7P 251586-22-8P 251586-23-9P 251586-24-0P 251586-25-1P
251586-26-2P 251586-27-3P 251586-28-4P 251586-29-5P 251586-30-8P
251586-31-9P 251586-32-0P 251586-33-1P 251586-34-2P 251586-35-3P
251586-36-4P 251900-41-1P 677013-17-1P 677013-18-2P 677013-56-8P
677013-57-9P 677013-80-8P 677013-81-9P 677013-82-0P 677013-83-1P
677013-84-2P 677013-85-3P 677013-86-4P 677013-87-5P 677013-88-6P
677013-89-7P 677013-91-1P 677013-92-2P 677013-94-4P 677013-95-5P
677013-96-6P 677013-97-7P 677013-99-9P 677014-00-5P 677014-01-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 677014-02-7P 677014-03-8P 677014-04-9P 677014-05-0P 677014-06-1P
677014-07-2P 677014-08-3P 677014-09-4P 677019-57-7P 677021-09-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 59-67-6, Nicotinic acid, reactions 79-09-4, Propionic acid, reactions 88-14-2, 2-Furoic acid 107-92-6, Butanoic acid, reactions 109-85-3, 2-Methoxyethylamine 138-59-0, Shikimic acid 142-62-1, Hexanoic acid, reactions 625-45-6, Methoxyacetic acid 2516-47-4,

Searcher : Shears 571-272-2528

Cyclopropanemethanamine 3222-56-8, 2-Methylnicotinic acid 4442-85-7, 2-Cyclohexylethylamine 5292-21-7, Cyclohexylacetic acid 5913-13-3, r 1-Cyclohexylethylamine 7154-73-6, 1-(2-Aminoethyl)pyrrolidine 16874-33-2, Tetrahydro-2-furoic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 101711-55-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptide antiangiogenic drugs)

IT 675886-06-3 675886-07-4 675886-08-5 675886-09-6
RL: PRP (Properties)
(unclaimed protein sequence; preparation of peptide antiangiogenic drugs)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 4 OF 6 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:5821 MARPAT
TITLE: Preparation of peptides having antiangiogenic activity
INVENTOR(S): Haviv, Fortuna; Henkin, Jack; Bradley, Michael F.; Kalvin, Douglas M.; Schneider, Andrew J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038347	A2	20010531	WO 2000-US32217	20001122
WO 2001038347	A3	20011129		
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2391386	AA	20010531	CA 2000-2391386	20001122
EP 1232183	A2	20020821	EP 2000-982219	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003530313	T2	20031014	JP 2001-540110	20001122
PRIORITY APPLN. INFO.:			US 1999-447225	19991122
			US 2000-709034	20001108
			WO 2000-US32217	20001122

AB Peptides Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 [Xaa1 is absent, H or an acyl group; Xaa2-Xaa10 represent certain amino acyl groups; Xaa11 is OH, an amino acid amide selected from D-alanylamide, D-alanylethylamide, azaglycylamide, glycylamide, glycylethylamide, sarcosylamide, serylamide, D-serylamide, a residue NH(CH2)sCHR3R4 or NHR5 [s = 0-8, R3 = H, alkyl, 5- to 6-membered cycloalkyl; R4 = H, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocyclyl, OH; R5 = H, OH, cycloalkyl (with provisos)]] or their pharmaceutically acceptable salts were prepared for inhibiting angiogenesis. Thus, Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-Pro-NHEt was prepared by the solid-phase method using Fmoc-protected amino acids. The synthesized peptides inhibited human endothelial cell migration by at least 50 % at concns. of 1 nM.

IC ICM C07K007-00
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

ST peptide prepn antiangiogenesis
IT Eye, disease
(diabetic retinopathy; preparation of peptides having antiangiogenic activity)
IT Eye, disease
(macula, degeneration; preparation of peptides having antiangiogenic activity)
IT Angiogenesis inhibitors
Antiarthritics
Antitumor agents
Psoriasis
(preparation of peptides having antiangiogenic activity)
IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides having antiangiogenic activity)
IT 341522-16-5P 341522-17-6P 341522-18-7P 341522-19-8P 341522-20-1P
341522-21-2P 341522-22-3P 341522-23-4P 341522-24-5P 341522-25-6P
341522-27-8P 341522-28-9P 341522-29-0P 341522-30-3P 341522-31-4P
341522-32-5P 341522-33-6P 341522-34-7P 341522-35-8P 341522-36-9P
341522-37-0P 341522-38-1P 341522-39-2P 341522-40-5P 341522-41-6P
341522-42-7P 341522-43-8P 341522-44-9P 341522-45-0P 341522-46-1P
341522-47-2P 341522-48-3P 341522-49-4P 341522-50-7P 341522-51-8P
341522-52-9P 341522-53-0P 341522-54-1P 341522-55-2P 341522-56-3P
341522-57-4P 341522-58-5P 341522-59-6P 341522-60-9P 341522-61-0P
341522-62-1P 341522-63-2P 341522-64-3P 341522-65-4P 341522-66-5P
341522-67-6P 341522-68-7P 341522-69-8P 341522-70-1P 341522-72-3P
341522-73-4P 341522-74-5P 341522-75-6P 341522-76-7P 341522-77-8P
341522-78-9P 341522-79-0P 341522-80-3P 341522-81-4P 341522-82-5P
341522-83-6P 341522-84-7P 341522-85-8P 341522-86-9P 341522-87-0P
341522-88-1P 341522-89-2P 341522-90-5P 341522-91-6P 341522-92-7P
341522-93-8P 341522-94-9P 341522-95-0P 341522-96-1P 341522-97-2P
341522-98-3P 341522-99-4P 341523-01-1P 341523-02-2P 341523-03-3P
341523-04-4P 341523-05-5P 341523-06-6P 341523-07-7P 341523-08-8P
341523-09-9P 341523-10-2P 341523-11-3P 341523-12-4P 341523-13-5P
341523-14-6P 341523-15-7P 341523-16-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides having antiangiogenic activity)

L36 ANSWER 5 OF 6 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:23191 MARPAT
TITLE: Preparation of peptide antiangiogenic drugs
INVENTOR(S): Henkin, Jack; Haviv, Fortuna; Bradley, Michael F.; Kalvin, Douglas M.; Schneider, Andrew J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9961476	A1	19991202	WO 1999-US11448	19990521
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2329250	AA	19991202	CA 1999-2329250	19990521
AU 9944075	A1	19991213	AU 1999-44075	19990521
AU 764277	B2	20030814		
EP 1078002	A1	20010228	EP 1999-927091	19990521
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO			
TR 200003442	T2	20010321	TR 2000-20000344	19990521
BR 9910639	A	20020115	BR 1999-10639	19990521
JP 2002516342	T2	20020604	JP 2000-550879	19990521
NZ 507912	A	20021025	NZ 1999-507912	19990521
NO 2000005890	A	20010112	NO 2000-5890	20001121
BG 105064	A	20010831	BG 2000-105064	20001218
PRIORITY APPLN. INFO.:			US 1998-83745	19980522
			US 1999-250574	19990216
			US 1999-277466	19990326
			WO 1999-US11448	19990521

AB Peptides A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 (A0 is H or an acyl group; A10 is OH or an amino acid amide; A1-9 are amino acyl residues) or their pharmaceutically acceptable salts, esters, solvates, or prodrugs were prepared for the treatment of angiogenesis. Thus, N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-NHEt was prepared by the solid-phase method and assayed for in vitro angiogenic activity (87.3% at 20 nM and 76.9 at 10 nM).

IC ICM C07K014-78
ICS A61K038-39; G01N033-68

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

ST peptide prepn antiangiogenic activity

IT Eye, disease
(diabetic retinopathy; preparation of peptide antiangiogenic drugs)

IT Eye, disease
(macula, degeneration; preparation of peptide antiangiogenic drugs)

IT Angiogenesis inhibitors
Antiarthritics
Antitumor agents
Psoriasis
(preparation of peptide antiangiogenic drugs)

IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 251579-31-4P 251579-32-5P 251579-33-6P 251579-34-7P 251579-35-8P
251579-36-9P 251579-37-0P 251579-38-1P 251579-39-2P 251579-40-5P
251579-41-6P 251579-42-7P 251579-43-8P 251579-44-9P 251579-45-0P
251579-46-1P 251579-47-2P 251579-48-3P 251579-49-4P 251579-50-7P
251579-51-8P 251579-52-9P 251579-53-0P 251579-54-1P 251579-55-2P

251579-56-3P 251579-57-4P 251579-58-5P 251579-59-6P 251579-60-9P
251579-61-0P 251579-62-1P 251579-63-2P 251579-64-3P 251579-65-4P
251579-66-5P 251579-67-6P 251579-68-7P 251579-69-8P 251579-70-1P
251579-71-2P 251579-72-3P 251579-73-4P 251579-74-5P 251579-75-6P
251579-76-7P 251579-77-8P 251579-78-9P 251579-79-0P 251579-80-3P
251579-81-4P 251579-82-5P 251579-83-6P 251579-84-7P 251579-85-8P
251579-86-9P 251579-87-0P 251579-88-1P 251579-89-2P 251579-90-5P
251579-91-6P 251579-92-7P 251579-93-8P 251579-94-9P 251579-95-0P
251579-96-1P 251579-97-2P 251579-98-3P 251579-99-4P 251580-00-4P
251580-01-5P 251580-02-6P 251580-03-7P 251580-04-8P 251580-05-9P
251580-06-0P 251580-07-1P 251580-08-2P 251580-09-3P 251580-10-6P
251580-11-7P 251580-12-8P 251580-13-9P 251580-14-0P 251580-15-1P
251580-16-2P 251580-17-3P 251580-18-4P 251580-19-5P 251580-20-8P
251580-21-9P 251580-22-0P 251580-23-1P 251580-24-2P 251580-25-3P
251580-26-4P 251580-27-5P 251580-28-6P 251580-29-7P 251580-30-0P
251580-31-1P 251580-32-2P 251580-33-3P 251580-34-4P 251580-35-5P
251580-36-6P 251580-37-7P 251580-38-8P 251580-39-9P 251580-40-2P
251580-41-3P 251580-42-4P 251580-43-5P 251580-44-6P 251580-45-7P
251580-46-8P 251580-47-9P 251580-48-0P 251580-49-1P 251580-50-4P
251580-51-5P 251580-52-6P 251580-54-8P 251580-55-9P 251580-57-1P
251580-58-2P 251580-60-6P 251580-61-7P 251580-63-9P 251580-64-0P
251580-66-2P 251580-67-3P 251580-69-5P 251580-70-8P 251580-72-0P
251580-73-1P 251580-75-3P 251580-76-4P 251580-78-6P 251580-79-7P
251580-81-1P 251580-82-2P 251580-84-4P 251580-85-5P 251580-87-7P
251580-88-8P 251580-90-2P 251580-91-3P 251580-93-5P 251580-94-6P
251580-96-8P 251580-97-9P 251580-99-1P 251581-00-7P 251581-02-9P
251581-03-0P 251581-05-2P 251581-07-4P 251581-08-5P 251581-10-9P
251581-11-0P 251581-13-2P 251581-14-3P 251581-15-4P 251581-16-5P
251581-17-6P 251581-18-7P 251581-19-8P 251581-20-1P 251581-21-2P
251581-22-3P 251581-23-4P 251581-24-5P 251581-25-6P 251581-26-7P
251581-27-8P 251581-28-9P 251581-29-0P 251581-30-3P 251581-31-4P
251581-32-5P 251581-33-6P 251581-34-7P 251581-35-8P 251581-36-9P
251581-37-0P 251581-38-1P 251581-39-2P 251581-40-5P 251581-41-6P
251581-42-7P 251581-43-8P 251581-44-9P 251581-45-0P 251581-46-1P
251581-47-2P 251581-48-3P 251581-49-4P 251581-50-7P 251581-51-8P
251581-52-9P 251581-53-0P 251581-54-1P 251581-55-2P 251581-56-3P
251581-57-4P 251581-58-5P 251581-59-6P 251581-60-9P 251581-61-0P
251581-62-1P 251581-63-2P 251581-64-3P 251581-65-4P 251581-66-5P
251581-67-6P 251581-68-7P 251581-69-8P 251581-70-1P 251581-71-2P
251581-72-3P 251581-73-4P 251581-74-5P 251581-75-6P 251581-76-7P
251581-77-8P 251581-78-9P 251581-79-0P 251581-80-3P 251581-81-4P
251581-82-5P 251581-83-6P 251581-84-7P 251581-85-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 251581-86-9P 251581-87-0P 251581-88-1P 251581-89-2P 251581-90-5P
251581-91-6P 251581-92-7P 251581-93-8P 251581-94-9P 251581-95-0P
251581-96-1P 251581-97-2P 251581-98-3P 251581-99-4P 251582-00-0P
251582-01-1P 251582-02-2P 251582-03-3P 251582-04-4P 251582-05-5P
251582-06-6P 251582-07-7P 251582-08-8P 251582-09-9P 251582-10-2P
251582-11-3P 251582-12-4P 251582-13-5P 251582-14-6P 251582-15-7P
251582-16-8P 251582-17-9P 251582-18-0P 251582-19-1P 251582-20-4P
251582-21-5P 251582-22-6P 251582-23-7P 251582-24-8P 251582-25-9P
251582-26-0P 251582-27-1P 251582-28-2P 251582-29-3P 251582-30-6P
251582-31-7P 251582-32-8P 251582-33-9P 251582-34-0P 251582-35-1P

Searcher : Shears 571-272-2528

251582-36-2P 251582-37-3P 251582-38-4P 251582-39-5P 251582-40-8P
251582-41-9P 251582-42-0P 251582-43-1P 251582-44-2P 251582-45-3P
251582-46-4P 251582-47-5P 251582-48-6P 251582-49-7P 251582-50-0P
251582-51-1P 251582-52-2P 251582-53-3P 251582-54-4P 251582-55-5P
251582-56-6P 251582-57-7P 251582-58-8P 251582-59-9P 251582-60-2P
251582-61-3P 251582-62-4P 251582-63-5P 251582-64-6P 251582-65-7P
251582-66-8P 251582-67-9P 251582-68-0P 251582-69-1P 251582-70-4P
251582-71-5P 251582-72-6P 251582-73-7P 251582-74-8P 251582-75-9P
251582-76-0P 251582-77-1P 251582-78-2P 251582-79-3P 251582-80-6P
251582-81-7P 251582-82-8P 251582-83-9P 251582-84-0P 251582-85-1P
251582-86-2P 251582-87-3P 251582-88-4P 251582-89-5P 251582-90-8P
251582-91-9P 251582-92-0P 251582-93-1P 251582-94-2P 251582-95-3P
251582-96-4P 251582-97-5P 251582-98-6P 251582-99-7P 251583-00-3P
251583-01-4P 251583-02-5P 251583-03-6P 251583-04-7P 251583-05-8P
251583-06-9P 251583-07-0P 251583-08-1P 251583-09-2P 251583-10-5P
251583-11-6P 251583-12-7P 251583-13-8P 251583-14-9P 251583-15-0P
251583-16-1P 251583-17-2P 251583-18-3P 251583-19-4P 251583-20-7P
251583-21-8P 251583-22-9P 251583-23-0P 251583-24-1P 251583-25-2P
251583-26-3P 251583-27-4P 251583-28-5P 251583-29-6P 251583-30-9P
251583-31-0P 251583-32-1P 251583-33-2P 251583-34-3P 251583-35-4P
251583-36-5P 251583-37-6P 251583-38-7P 251583-39-8P 251583-40-1P
251583-41-2P 251583-42-3P 251583-43-4P 251583-44-5P 251583-45-6P
251583-46-7P 251583-47-8P 251583-48-9P 251583-49-0P 251583-50-3P
251583-51-4P 251583-52-5P 251583-53-6P 251583-54-7P 251583-55-8P
251583-56-9P 251583-57-0P 251583-58-1P 251583-59-2P 251583-60-5P
251583-61-6P 251583-62-7P 251583-63-8P 251583-64-9P 251583-65-0P
251583-66-1P 251583-67-2P 251583-68-3P 251583-69-4P 251583-70-7P
251583-71-8P 251583-72-9P 251583-73-0P 251583-74-1P 251583-75-2P
251583-76-3P 251583-77-4P 251583-78-5P 251583-79-6P 251583-80-9P
251583-81-0P 251583-82-1P 251583-83-2P 251583-84-3P 251583-85-4P
251583-86-5P 251583-87-6P 251583-88-7P 251583-89-8P 251583-90-1P
251583-91-2P 251583-92-3P 251583-93-4P 251583-96-7P 251583-97-8P
251583-98-9P 251583-99-0P 251584-00-6P 251584-01-7P 251584-02-8P
251584-03-9P 251584-04-0P 251584-05-1P 251584-06-2P 251584-07-3P
251584-08-4P 251584-09-5P 251584-10-8P 251584-11-9P 251584-12-0P
251584-13-1P 251584-14-2P 251584-15-3P 251584-16-4P 251584-17-5P
251584-18-6P 251584-19-7P 251584-20-0P 251584-21-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 251584-22-2P 251584-23-3P 251584-24-4P 251584-25-5P 251584-26-6P
251584-27-7P 251584-28-8P 251584-29-9P 251584-30-2P 251584-31-3P
251584-32-4P 251584-33-5P 251584-34-6P 251584-35-7P 251584-36-8P
251584-37-9P 251584-38-0P 251584-39-1P 251584-40-4P 251584-41-5P
251584-42-6P 251584-43-7P 251584-44-8P 251584-45-9P 251584-46-0P
251584-47-1P 251584-48-2P 251584-49-3P 251584-50-6P 251584-51-7P
251584-52-8P 251584-53-9P 251584-54-0P 251584-55-1P 251584-56-2P
251584-57-3P 251584-58-4P 251584-59-5P 251584-60-8P 251584-61-9P
251584-62-0P 251584-63-1P 251584-64-2P 251584-65-3P 251584-66-4P
251584-67-5P 251584-68-6P 251584-69-7P 251584-70-0P 251584-71-1P
251584-72-2P 251584-73-3P 251584-74-4P 251584-75-5P 251584-76-6P
251584-77-7P 251584-78-8P 251584-79-9P 251584-80-2P 251584-81-3P
251584-82-4P 251584-83-5P 251584-84-6P 251584-85-7P 251584-86-8P
251584-87-9P 251584-88-0P 251584-89-1P 251584-90-4P 251584-91-5P
251584-92-6P 251584-93-7P 251584-94-8P 251584-95-9P 251584-96-0P

Searcher : Shears 571-272-2528

251584-97-1P 251584-98-2P 251584-99-3P 251585-00-9P 251585-01-0P
251585-02-1P 251585-03-2P 251585-04-3P 251585-05-4P 251585-06-5P
251585-07-6P 251585-08-7P 251585-09-8P 251585-10-1P 251585-11-2P
251585-12-3P 251585-13-4P 251585-14-5P 251585-15-6P 251585-16-7P
251585-17-8P 251585-18-9P 251585-19-0P 251585-20-3P 251585-21-4P
251585-22-5P 251585-23-6P 251585-24-7P 251585-25-8P 251585-26-9P
251585-27-0P 251585-28-1P 251585-29-2P 251585-30-5P 251585-31-6P
251585-32-7P 251585-33-8P 251585-34-9P 251585-35-0P 251585-36-1P
251585-37-2P 251585-38-3P 251585-39-4P 251585-40-7P 251585-41-8P
251585-42-9P 251585-43-0P 251585-44-1P 251585-45-2P 251585-46-3P
251585-47-4P 251585-48-5P 251585-49-6P 251585-50-9P 251585-51-0P
251585-52-1P 251585-53-2P 251585-54-3P 251585-55-4P 251585-56-5P
251585-57-6P 251585-58-7P 251585-59-8P 251585-60-1P 251585-61-2P
251585-62-3P 251585-63-4P 251585-64-5P 251585-65-6P 251585-66-7P
251585-67-8P 251585-68-9P 251585-69-0P 251585-70-3P 251585-71-4P
251585-72-5P 251585-73-6P 251585-74-7P 251585-75-8P 251585-76-9P
251585-77-0P 251585-78-1P 251585-79-2P 251585-80-5P 251585-81-6P
251585-82-7P 251585-83-8P 251585-84-9P 251585-85-0P 251585-86-1P
251585-87-2P 251585-89-4P 251585-91-8P 251585-93-0P 251585-95-2P
251585-97-4P 251585-99-6P 251586-01-3P 251586-03-5P 251586-05-7P
251586-07-9P 251586-09-1P 251586-11-5P 251586-13-7P 251586-15-9P
251586-16-0P 251586-17-1P 251586-18-2P 251586-19-3P 251586-20-6P
251586-21-7P 251586-22-8P 251586-23-9P 251586-24-0P 251586-25-1P
251586-26-2P 251586-27-3P 251586-28-4P 251586-29-5P 251586-30-8P
251586-32-0P 251586-33-1P 251586-34-2P 251586-35-3P 251586-36-4P
251900-41-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide antiangiogenic drugs)

IT 59-67-6, Nicotinic acid, reactions 79-09-4, Propionic acid, reactions 88-14-2, 2-Furoic acid 107-92-6, Butanoic acid, reactions 109-85-3, 2-Methoxyethylamine 138-59-0, Shikimic acid 142-62-1, Hexanoic acid, reactions 625-45-6, Methoxyacetic acid 2516-47-4, Cyclopropanemethanamine 3222-56-8, 2-Methylnicotinic acid 4442-85-7, 2-Cyclohexylethylamine 5292-21-7, Cyclohexylacetic acid 5913-13-3, r 1-Cyclohexylethylamine 7154-73-6, 1-(2-Aminoethyl)pyrrolidine 16874-33-2, Tetrahydro-2-furoic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 101711-55-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptide antiangiogenic drugs)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 6 OF 6 MARPAT COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 125:87217 MARPAT
TITLE: Preparation of polymer-bound luteinizing hormone releasing factor analogs with antitumor activity.
INVENTOR(S): Lovas, Sandor; Murphy, Richard F.; Toth, Geza; Kalnay, Adrienn; Gaal, Dezso; Palyi, Istvan; Turi, Gizella; Vincze, Borbala; Mezo, Imre; et al.
PATENT ASSIGNEE(S): Ukraine
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604927	A1	19960222	WO 1995-US10054	19950809
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2173727	AA	19960222	CA 1995-2173727	19950809
AU 9533616	A1	19960307	AU 1995-33616	19950809
EP 728012	A1	19960828	EP 1995-930123	19950809
EP 728012	B1	20040218		
R: DE, FR, GB, IT				
JP 09508142	T2	19970819	JP 1995-507451	19950809
US 6664369	B1	20031216	US 2000-269954	20000727
PRIORITY APPLN. INFO.:			HU 1994-2328	19940810
			HU 1994-2329	19940810
			WO 1995-US10054	19950809

AB YWuVzXrAk [Y = R3[CHR1CHR2CH(CO-)C(CO-)]nH; n = 10-400; 1 of R1, R2 = H, the other = 2-oxopyrrolidin-1-yl; R3 = polymerization-initiating group, preferably Me2CCN; W = OH (or alkali metal salt thereof); V = alkylamino, bond; X = amino acid,r oligopeptide; A = pharmacol. active polypeptide; r = 0 to 0.2n; k ≤ r; z = 0 to n-r; u = n to 2n-r] and nonpolymer-bound peptides, were prepared Thus, N-vinylpyrrolidone-maleic anhydride copolymer was stirred 3 h with H-Gly-Phe-Leu-Gly nitrophenyl ester and Et3N in DMF to give after aqueous hydrolysis poly(N-Vinylpyrrolidone-maleic acid)-Gly-Phe-Leu-Gly nitrophenyl ester. The latter in DMF was stirred 24 h with Ac-D-Trp1,3,D-Cpa2,Lys5,[β-Asp(DEA)]6,D-Ala10-HGnRH and Et3N to give Ac-D-Trp1,3,D-Cpa2,Lys[poly(N-vinylpyrrolidone-maleic acid)-Gly-Phe-Leu-Gly-] 5,[β-Asp(DEA)]6,D-Ala10-HGnRH. The latter at 50 μM in MCF-7 cell cultures showed 93% inhibition of colony formation.

IC ICM A61K038-00
ICS C07K005-00; C07K007-00; C07K017-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

ST gnrh analog polymer bound prepn anticancer

IT Immunostimulants
Neoplasm inhibitors
(preparation of polymer-bound GNRH analogs with antitumor activity)

IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymer-bound, preparation of polymer-bound GNRH analogs with antitumor activity)

IT 111-26-2DP, 1-Hexanamine, poly(N-vinylpyrrolidone-maleic acid)-bound 9034-40-6DP, Gnrh, analogs 178414-67-0DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-68-1DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-69-2DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-70-5DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-71-6DP,

poly(N-vinylpyrrolidone-maleic acid)-bound 178414-72-7DP,
poly(N-vinylpyrrolidone-maleic acid)-bound 178414-73-8DP,
poly(N-vinylpyrrolidone-maleic acid)-bound 178414-74-9DP,
poly(N-vinylpyrrolidone-maleic acid)-bound 178414-75-0DP,
poly(N-vinylpyrrolidone-maleic acid)-bound 178414-76-1DP,
poly(N-vinylpyrrolidone-maleic acid)-bound 178414-77-2DP,
poly(N-vinylpyrrolidone-maleic acid)-bound 178414-78-3DP,
poly(N-vinylpyrrolidone-maleic acid)-bound 178414-80-7P 178414-82-9P
178414-83-0P 178414-85-2P 178414-86-3P 178414-87-4P 178414-89-6P
178414-90-9P 178414-95-4P 178414-96-5P 178414-97-6P 178414-98-7P
178414-99-8P 178415-00-4P 178415-01-5P 178415-02-6P 178415-03-7P
178415-04-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polymer-bound GNRH analogs with antitumor activity)

IT 108-24-7, Acetic anhydride 111-26-2, 1-Hexanamine 2389-45-9, BOC-Lys(Z)-OH 4530-20-5 5241-64-5 15761-39-4D, resin-bound 26837-56-9, N-Vinylpyrrolidone-maleic anhydride copolymer 52671-12-2 65360-23-8, SJ 1004 73821-97-3 84624-27-1 87565-51-3, MI-1544 147859-97-0, Luteinizing hormone-releasing factor III (Petromyzon marinus) 176429-96-2, MI-1892 178414-81-8 178414-84-1 178414-88-5 178414-91-0 178414-92-1 178414-93-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of polymer-bound GNRH analogs with antitumor activity)

IT 13111-35-8DP, poly(N-vinylpyrrolidone-maleic acid)-bound 102685-48-3DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-65-8DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-66-9DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-79-4P 178414-94-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of polymer-bound GNRH analogs with antitumor activity)

FILE 'MARPATPREV' ENTERED AT 13:00:37 ON 22 NOV 2004

L32 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 16 29
GGCAT IS PCY AT 16

Searcher : Shears 571-272-2528

GGCAT IS MCY UNS AT 29
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L37 0 SEA FILE=MARPATPREV SSS FUL L32 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 12 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FILE 'REGISTRY' ENTERED AT 13:01:07 ON 22 NOV 2004
L38 4 S EHWSYL/SQSP

Seq.

L38 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 581927-52-8 REGISTRY
CN Protein (Klebsiella pneumoniae strain ATCC202080 clone US6610836-SEQID-13292 open reading frame-encoded) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2592: PN: US6610836 SEQID: 13292 claimed protein
CI MAN
SQL 573

SEQ
1 SPSRLRWVNS SPYFNREVFL QFDYIIIGAG SAGNVLATRL TEDPNTTVLL
51 LEAGGPDYRF DFRTQMPAAL AYPLQGKRYN WAYETEPEPY MNNRRMECGR
101 GKGLGGSSLI NGMCYIRGNA MDLDNWAKEP GLEHWSYLDC LPYYRKAETR
151 DIGPNDYHGG DGPVSVTTPK PGNNPLFEAM VEAGVQAGYP RTDDLNGYQQ
201 EGFGPMDRTV TPQGRRASTA RGYLDQARGR PNLTIRTHAL TDHIIFAGKR
251 AVGVEWLEGE STIPSKATAN KEVLLCAGAI ASPQILQRSG VGNPELLRQF
301 DIPVVHDLPG VGENLQDHLE MYLQYECKEP VSLYPALQWW NQPKIGAEWL
351 FGGTGIGASN QFEAGGFIRS RAEFAWPNIQ YHFLPVAINY NGSNAVKEHG
401 FQCHVGSMRS PSRGHVRLKS RDPHAHPAIL FNYMSHEQDW QEFRDAIRIT
451 REIMNQPALD KYRGREISPG IECQSDAELD EFVRNHAETA FHPCGTCKMG
501 YDEMAVVDGE GRVHGLEGLR VVDASIMPQI ITGNLNATTI MIGEKMADAI
551 RGRQPLPRST ATYYVAGDAP VRR

HITS AT: 133-138

REFERENCE 1: 139:192571

L38 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477074-93-4 REGISTRY
CN Protein (Klebsiella pneumoniae clone KPN304388 essential) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2036: PN: WO02077183 SEQID: 60036 claimed protein
CI MAN
SQL 554

```
SEQ      1 MQFDYIIIGA GSAGNVLATR LTEDPNTTVL LLEAGGPDYR FDFRTQMPAA
        51 LAYPLQGKRY NWAYETEPEP YMNNRRMECG RGKGLGGSSL INGMCYIRGN
       101 AMDLDNWAKE PGLEHWSYLD CLPYYRKAET RDIGPNDYHG GDGPVSVTTP
                       ======
       151 KPGNNPLFEA MVEAGVQAGY PRTDDLNGYQ QEGFGPMDRT VTPQGRRAST
       201 ARGYLDQARG RPNLTIRTHA LTDHIIFAGK RAVGVEWLEG ESTIPSKATA
       251 NKEVLLCAGA IASPQILQRS GVGNPELLRQ FDIPVVHDLP GVGENLQDHL
       301 EMYLQYECKE PVSLYPALQW WNQPKIGAEW LFGGTGIGAS NQFEAGGFIR
       351 SRAEFAWPNI QYHFLPVAIN YNGSNAVKEH GFQCHVGSMR SPSRGHVRLK
       401 SRDPHAHPAI LFNYMSHEQD WQEFRDAIRI TREIMNQPAL DKYRGREISP
       451 GIECQSDAEL DEFVRNHAET AFHPCGTCKM GYDEMAVVDG EGRVHGLEGL
       501 RVVDASIMPQ IITGNLNATT IMIGEKMADA IRGRQPLPRS TATYYVAGDA
       551 PVRR
HITS AT:    114-119

REFERENCE   1:  138:1095

L38  ANSWER 3 OF 4  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   465609-93-2  REGISTRY
CN   Protein (Plasmodium falciparum strain 3D7 gene PF10-0219) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   GenBank AAN35416
CN   GenBank AAN35416 (Translated from: GenBank AE014832)
CI   MAN
SQL  891

SEQ      1 MVKKDKKSKE KKEKLKLKKE KQKLKSLKSK KKKKDTLSDE DFDTICLYYE
        51 NLNKKDKFGH ININTTSNNT FVECEKPSPR SNCSITFIND EEFILFGGEY
       101 NDNNELISYN DLFKYNIVKN KWKYYFTTSK KPKPRCSHQT VYFNKKLYIF
       151 GGELCTNTQF FHYNDFWSFD LKNNVFEEIE TKNKKDDNKP SPRSGHRMIL
       201 WKNYIVMFGG FFDNGKSIEY FNDLYIYIIN SNIWINLTNV YMDSLFKRLT
       251 ENNSSNNDNN LSISSEKKKD LNKGKNSQIL KSKFFKNFDL DSFMPSKRSS
       301 VCLFTDMKYQ KIYIYGGYSQ IKNTTRNAIG FYFNDMWILN INLINEDNIS
       351 VNFKKLKKSI FQPCKRTGFS TCIYKNSLIL FGGVFDKKVE NNSKKIDNPN
       401 NNNNMLEESL NLKSLFFNDL YLFDMNKEHW SYLNIKDKEE TKELNKTSKA
                                          === ===
       451 NKKNHEKLEE NKIGTNIKKD KFQQMEREIY YEENNNNNNN NNNNKTQSKY
       501 EETSDGHVSS CFSDDNDEDY YSNVFVYFDE NGKRQIIKIE KEEKNKSSYN
       551 EKKDFDDVLK VEENNDYLNH SLDEEKNINI DKLIDNHSVF LQTKDIITTG
       601 NGNKVTKIFG DENKHCQNIS NLPLNETILY VPLNNTTNSE NFMYSQELND
       651 STNMIKVEHI NDTENVDEET CKEDSVDEDM KDNSNSDSDS NKEEKKKKFV
       701 ISEEEPIGRI NSHIFVLNKN LYVYGGMYEY KNNEIILSDY WKINIFKREK
       751 WELLDKGNLD DIYLEESDMS STISINDDDK DEKEIEDLII CSKIKKLEKK
       801 IKELDEGLAL DIKENLNEFF LRTKDHWLKE LNKISETKEI RKEAFYLCEQ
       851 KYKVIKKYYN KIQKYKELLM EDDEERSISE TISSEQEQSS N
HITS AT:    428-433

REFERENCE   1:  137:289734

L38  ANSWER 4 OF 4  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   112642-13-4  REGISTRY
CN   Luteinizing hormone-releasing factor (swine), 1-L-glutamic
     acid-6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- (9CI)  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
```

CN Luteinizing hormone-releasing factor (pig), 1-L-glutamic acid-6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-
SQL 9

SEQ 1 EHWSYLLRP
======
HITS AT: 1-6

REFERENCE 1: 108:82207

FILE 'CAPLUS' ENTERED AT 13:01:52 ON 22 NOV 2004
L39 4 S L38
L40 3 S L39 NOT L28

L40 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 07 Sep 2003
ACCESSION NUMBER: 2003:697220 CAPLUS
DOCUMENT NUMBER: 139:192571
TITLE: Nucleic acid and encoded amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
INVENTOR(S): Breton, Gary L.; Osborne, Mark
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA
SOURCE: U.S., 932 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6610836	B1	20030826	US 2000-489039		20000127
PRIORITY APPLN. INFO.:			US 1999-117747P	P	19990129

AB The invention provides 7171 isolated polypeptide and 7171 genomic nucleic acid sequences derived from Klebsiella pneumoniae strain 93,19097 (ATCC 202080) that are useful in diagnosis and therapy of pathol. conditions. The nucleotide sequences include those of two naturally occurring plasmids in K. pneumoniae. Antibodies against the polypeptides, and methods for the production of recombinant polypeptides are also provided. The invention also provides methods for the detection, prevention, and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of four records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].
IT **581927-52-8**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; nucleic acid and encoded amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics)

L40 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 14 Oct 2002
ACCESSION NUMBER: 2002:781491 CAPLUS
DOCUMENT NUMBER: 138:1095
TITLE: Essential genes in microorganisms and their use as

targets for antisense inhibition of proliferation and antibiotic screening

INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 22
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XN9107	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 2001-815242	A	20010321
US 2001-948993	A	20010906
US 2001-342923P	P	20011025
US 2002-72851	A	20020208
US 2002-362699P	P	20020306
WO 2002-US9107	A	20020321
US 2000-191078P	P	20000321
US 2000-206848P	P	20000523
US 2000-207727P	P	20000526
US 2000-242578P	P	20001023
US 2000-253625P	P	20001127
US 2000-257931P	P	20001222
US 2001-269308P	P	20010216

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, and

Staphylococcus aureus. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **477074-93-4**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L40 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 04 Oct 2002
ACCESSION NUMBER: 2002:752115 CAPLUS
DOCUMENT NUMBER: 137:289734
TITLE: Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14
AUTHOR(S): Gardner, Malcolm J.; Shallom, Shamira J.; Carlton, Jane M.; Salzberg, Steven L.; Nene, Vishvanath; Shoaibi, Azadeh; Ciecko, Anne; Lynn, Jeffery; Rizzo, Michael; Weaver, Bruce; Jarrahi, Behnam; Brenner, Michael; Parvizi, Babak; Tallon, Luke; Moazzez, Azita; Granger, David; Fujii, Claire; Hansen, Cheryl; Pederson, James; Feldblyum, Tamara; Peterson, Jeremy; Suh, Bernard; Angiuoli, Sam; Pertea, Mihaela; Allen, Jonathan; Selengut, Jeremy; White, Owen; Cummings, Leda M.; Smith, Hamilton O.; Adams, Mark D.; Venter, J. Craig; Carucci, Daniel J.; Hoffman, Stephen L.; Fraser, Claire M.
CORPORATE SOURCE: The Institute for Genomic Research, Rockville, MD, 20850, USA
SOURCE: Nature (London, United Kingdom) (2002), 419(6906), 531-534
CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The mosquito-borne malaria parasite Plasmodium falciparum kills an estimated 0.7-2.7 million people every year, primarily children in sub-Saharan Africa. Without effective interventions, a variety of factors-including the spread of parasites resistant to antimalarial drugs and the increasing insecticide resistance of mosquitoes-may cause the number of malaria cases to

double over the next two decades. To stimulate basic research and facilitate the development of new drugs and vaccines, the genome of Plasmodium falciparum clone 3D7 has been sequenced using a chromosome-by-chromosome shotgun strategy. This report describes nucleotide sequences of chromosomes 10, 11 and 14, and a re-anal. of the chromosome 2 sequence. These chromosomes represent about 35% of the 23-megabase P. falciparum genome. The sequences are deposited in GenBank/EMBL/DDBJ under accession nos. AE001362.2 (chromosome 2), AE014185 (chromosome 10), AE014186 (chromosome 11), and AE014187 (chromosome 14).

IT **465609-93-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; complete sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

(FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 13:02:33 ON 22 NOV 2004)
L41 0 S L38

FILE 'HOME' ENTERED AT 13:02:41 ON 22 NOV 2004